The European Commission approved Vyloy (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin 18.2 positive.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted positive opinions recommending approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, for two indications in gynecologic cancers.
Bayer announced the submission of a supplemental new drug application to FDA for the oral androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”
Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report.
The 2024 Albert Lasker Basic Medical Research Award went to Zhijian “James” Chen. The Lasker~DeBakey Clinical Medical Research Award went to Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov. The Lasker~Bloomberg Public Service Award went to Quarraisha Abdool Karim and Salim S. Abdool Karim.
Tampa General Hospital and Mass General Brigham announced a strengthening of their affiliation with the development of new programs and services, including a bone marrow transplant program and CAR T therapy program, at TGH.
Robert R. Jenq was named director of the microbiome program at City of Hope and clinical professor in the Department of Hematology and Hematopoietic Cell Transplantation.
The Sandra and Edward Meyer Cancer Center of Weill Cornell Medicine and New York-Presbyterian Hospital has appointed a trio of physicians and researchers to oversee the center’s first Office of Diversity Equity and Inclusion: Eloise Chapman-Davis, Minerva A. Romero Arenas, and Monica L. Guzman.
